Evidence map›Paper›PMID 24419514›Full record

ArticleBone marrow transplantation2014

Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation.

M Sato, H Nakasone, K Terasako-Saito, K Sakamoto, R Yamazaki, Y Tanaka, Y Akahoshi, H Nakano, T Ugai, H Wada and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

M SatoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
H NakasoneDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
K Terasako-SaitoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
K SakamotoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
R YamazakiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Y TanakaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Y AkahoshiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
H NakanoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
T UgaiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
H WadaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
R YamasakiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Y IshiharaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
K KawamuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
M AshizawaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
S-i KimuraDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
M KikuchiDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
A TaniharaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
J KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
S KakoDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
J NishidaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Y KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that the baseline C-reactive protein level did not predict infectious events after hematopoietic cell transplantation (HCT). Procalcitonin (PCT) has recently emerged as a powerful biomarker for the early diagnosis of bacterial infection. We evaluated the ability of the baseline PCT level to predict early infectious events after HCT in 79 recipients who received HCT between 2008 and 2012. The high-PCT group (≥ 0.07 ng/mL, n=27) frequently experienced documented infection (DI) (21.2% vs 44.4% at day 30, P=0.038) and bloodstream infection (BSI) (15.4% vs 37.0% at day 30, P=0.035). In a multivariate analysis, however, the baseline PCT level was not significantly associated with DI (HR 2.01, P=0.089) or BSI (HR 2.28, P=0.084). Localized infection, such as anal canal problems, before the start of conditioning was seen in 26 patients. When we stratified the patients according to the presence of elevated PCT and localized infection, the group with elevated PCT and localized infection (n=17) was significantly associated with increased DI (HR 3.40, P=0.0074) and BSI (HR 3.59 P=0.0078) after HCT. A larger prospective observation is warranted to confirm the impact of the baseline PCT level and clinical features on the outcome of HCT.

Indexed as

Bacterial InfectionsBiomarkersCalcitoninCalcitonin Gene-Related PeptideC-Reactive ProteinCryopreservationFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPredictive Value of TestsProtein PrecursorsTransplantation ConditioningTransplantation, HomologousBiomarkersCALCA protein, humanCalcitoninCalcitonin Gene-Related PeptideC-Reactive ProteinProtein Precursors

Identifiers

PMID24419514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.